Tag: BNT162b2
Study: Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine
An investigation by five German scientists of the variability of batches of the Pfizer/BionTech BNT162b2 mRNA COVID-19 vaccine, using a recent Danish study as the basis for their study. More...
Preprint: Intracellular Reverse Transcription into DNA of mRNA Vaccine
We show that BNT162b2 mRNA is reverse transcribed intracellularly into DNA in as fast as 6 hours upon BNT162b2 exposure. More...
Norway: Nursing home deaths after Pfizer-BioNTech coronavirus vaccination
In the period 27 December 2020 to 15 February 2021, about 29,400 of Norway’s roughly 35,000 nursing home patients were vaccinated with the [Pfizer–BioNTech] mRNA vaccine BNT162b2. More...
SARS-CoV-2 coronavirus variants B.1.351 and P.1 escape from neutralizing antibodies
“In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. More...
Evidence for increased vaccine breakthrough rates of coronavirus variants of concern in BNT162b2 Pfizer-BionTech mRNA vaccinated individuals
Here, we performed a case-control study that examined whether BNT162b2 (Pfizer-BionTech) vaccinees with documented SARS-CoV-2 infection were more likely to become infected with B.1.1.7 or B.1.351 compared with unvaccinated individuals. More...
Switzerland: Stage III hypertension in patients after mRNA-based SARS-CoV-2 coronavirus vaccination with Pfizer/Biontech & Moderna
On January 11th 2021, the vaccination Center in Lausanne, a city of 140’000 inhabitants in western Switzerland, started the COVID-19 vaccination with mRNA-based vaccines. More...